¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦42Â÷ 2023³âµµ ´ëÇѽŰæ°úÇÐȸ Ãß°èÇмú´ëȸ DAY 1 : 2023-11-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦42Â÷ 2023³âµµ ´ëÇѽŰæ°úÇÐȸ Ãß°èÇмú´ëȸ DAY 1 : 2023-11-10
±³À°ÀÏÀÚ : 2023-11-10
±³À°Àå¼Ò : ¼­¿ï ½ºÀ§½º±×·£µå È£ÅÚ ÄÁº¥¼Ç¼¾ÅÍ 3F Emerald Hall A,B , 4F Convention Hall A,B,C

±³À°ÁÖÁ¦ : Á¦42Â÷ 2023³âµµ ´ëÇѽŰæ°úÇÐȸ Ãß°èÇмú´ëȸ DAY 1

ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
´ã´çÀÚ : ´ëÇѽŰæ°úÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-737-6530  

À̸ÞÀÏ : kna@neuro.or.kr

±³À°Á¾·ù : ½Å°æ°ú

Âü¼®¿¹»óÀÎ : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 19 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 160,000¿ø  

ºñ°í »çÀüµî·Ïºñ: Á¤È¸¿ø- Àü¹®ÀÇ 10¸¸¿ø, ÀüÀÓÀÇ,±ºº¹¹«- 6¸¸¿ø, ÁØȸ¿ø- Àü°øÀÇ 6¸¸¿ø,  ºñȸ¿ø- Ÿ°ú 16¸¸¿ø, ÇDZ³À°ÀÚ(¿¬±¸¿ø µî) 8¸¸¿ø, ÀÇ°ú´ëÇРȤÀº ÀÇÀü¿ø»ý 1¸¸¿øÇöÀåµî·Ïºñ: Á¤È¸¿ø- Àü¹®ÀÇ 12¸¸¿ø, ÀüÀÓÀÇ,±ºº¹¹«- 8¸¸¿ø, ÁØȸ¿ø- Àü°øÀÇ 8¸¸¿ø, ºñȸ¿ø- Ÿ°ú 16¸¸¿ø, ÇDZ³À°ÀÚ 8¸¸¿ø, ÀÇ°ú´ëÇРȤÀº ÀÇÀü¿ø»ý 2¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 08:30~08:50 Burden of cluster headache in Korea ±è¼ö°æ(°æ»ó´ëº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 08:50~09:10 New findings in phenotype and clinical characteristics in Korea ±èº´¼ö(ÀÌÈ­ÀÇ´ë¸ñµ¿º´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 09:10~09:30 Treatment and prognosis of cluster headache in Korea À̹ÌÁö(¼­¿ï´ëº´¿ø)

Åä·Ð 11¿ù 10ÀÏ Convention Hall A (4F) 09:30~09:40 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 08:30~08:50 Upcoming blood biomarker in AD °í¼ºÈ£(ÇѾç´ë±¸¸®º´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 08:50~09:10 AD CSF biomarker in clinical practice ¹Ú¼±¾Æ(¾ÆÁִ뺴¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 09:10~09:30 Digital biomarker for early stage of AD À±¿µÃ¶(Á߾Ӵ뺴¿ø)

Åä·Ð 11¿ù 10ÀÏ Convention Hall B (4F) 09:30~09:40 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall C (4F) 08:30~08:50 Brain – º´·Â, ÁøÂû, ü¾×, ¿µ»ó°Ë»ç¿¡ µû¸¥ Áø´Ü°ú °¨º°, ¹Ýµå½Ã Æ÷ÇԵǾî¾ß ÇÒ ³»¿ëÀº? ÇöÀç¿ø(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall C (4F) 08:50~09:10 Optic nerve – ²À È®ÀÎÇØ¾ß ÇÒ º´·Â°ú ÁøÂû ¼Ò°ß, ¿µ»ó°¨º°¹ý ÀÌÀºÀç(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall C (4F) 09:10~09:30 Spine – ²À È®ÀÎÇØ¾ß ÇÒ º´·Â°ú ÁøÂû ¼Ò°ß, ¿µ»ó°¨º°¹ý ±Ç¼ø¿í(ÀÎÇϴ뺴¿ø)

Åä·Ð 11¿ù 10ÀÏ Convention Hall C (4F) 09:30~09:40 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall A (3F) 08:30~09:00 Video Session: Neuro-ophthalmology/otology °­ºÀÈñ(´Ü±¹´ëº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall A (3F) 09:00~09:30 Video Session:Sleep º¯Á¤ÀÍ(°­µ¿°æÈñ´ëº´¿ø)

Åä·Ð 11¿ù 10ÀÏ Emerald Hall A (3F) 09:30~09:40 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall B (3F) 08:30~08:50 Periprocedural stroke È«Áö¸¸(¾ÆÁִ뺴¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall B (3F) 08:50~09:10 Nonconvulsive status epilepticus: monitoring and management ¹ÚÇý¸®(ÀÎÁ¦´ëÀÏ»ê¹éº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall B (3F) 09:10~09:30 Acute encephalopathy associated with medications ±èÅÂÁ¤(¼­¿ï´ëº´¿ø)

Åä·Ð 11¿ù 10ÀÏ Emerald Hall B (3F) 09:30~09:40 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall  (4F) 10:05~11:05 Antiepileptic Drugs in New Drug Era À̺´ÀÎ(ÇѾç´ëÇб³ ¸íÁöº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall  (4F) 11:10~12:00 AI for Brain, Brain for AI ÀÓâȯ(ÇѾç´ë À¶ÇÕÀüÀÚ°øÇкÎ)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall B (3F) 13:10~14:10 Self Compassion - »îÀÌ Èû°Ü¿ï ¶§ ³ª¿¡°Ô ´ÙÁ¤ÇÑ Ä£±¸ µÇ±â ±Ç¼±¾Æ(°ø°¨°úÀÚºñ¿¬±¸¼Ò ¼ÒÀå)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 14:20~14:35 Facial palsy: stroke mimic or stroke chameleon? È«ÀÇÂù(ÀÎÇϴ뺴¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 14:35~14:50 What made a vegan lady have a seizure? ȲÇý¸®(°Ç±¹´ëº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 14:50~15:05 Associative visual object agnosia and apperceptive prosopagnosia after aortic dissection surgery ÃÖ¼®È£(ºÎ»ê´ëº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 15:05~15:20 The discrepancy between the intensity of pendular nystagmus and patient-reported outcome: A case report ÃÖÇÏ¿µ(Ãæ³²´ëº´¿ø)

ÈÞ½Ä 11¿ù 10ÀÏ Convention Hall A (4F) 15:20~15:30 Break ()

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 15:30~15:45 A case of cerebral venous thrombosis after nitrous oxide abuse À±¼ÒÁ¤(¿¬¼¼´ë¼¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 15:45~16:00 A case of transient epileptic amnesia mimicking recurrent transient global amnesia ±èÇѺû(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 16:00~16:15 Silent leaks, unsteady steps: Unraveling spontaneous intracranial hypotension ±è½Â¾Ö(¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall A (4F) 16:15~16:30 Diplopia in a 24-year-old woman with easy bruising °­Çö¿ì(°í·Á´ë¾È¾Ïº´¿ø)

±âŸ 11¿ù 10ÀÏ Convention Hall A (4F) 16:30~16:40 ÃÑÆò ¹× Á¤¸® ()

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 14:20~14:30 South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face-to-face and video communication platforms in mild cognitive impairment (SUPERBRAIN-MEET): a randomized controlled trial ÃÖ¼ºÇý(ÀÎÇϴ뺴¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 14:30~14:40 Effects of repetitive transcranial magnetic stimulation on reduced seizure frequency in patients with drug-resistant epilepsy: an open-label randomized trial ±èÇÏ¿è(°í·Á´ë¾È¾Ïº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 14:40~14:50 Differences in neuropathology between nitroglycerin-Induced mouse model of episodic and chronic migraine ¼ÕÁ¾Èñ(ÇѸ²´ëÃáõ¼º½Éº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 14:50~15:00 Genome-wide survival analysis revealed HS1BP3 and APOE loci associated with Parkinson¡¯s disease dementia Á¶¼º¾ç(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 15:00~15:10 Alterations in the multilayer network in patients with rapid eye movement sleep behavior disorder À̵¿¾Æ(ÀÎÁ¦´ëÇØ¿î´ë¹éº´¿ø)

Åä·Ð 11¿ù 10ÀÏ Convention Hall B (4F) 15:10~15:20 Q&A ()

ÈÞ½Ä 11¿ù 10ÀÏ Convention Hall B (4F) 15:20~15:30 Break ()

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 15:30~15:40 Factors associated with low rate of intravenous thrombolysis in Korea À̰溹(¼øõÇâ´ëº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 15:40~15:50 Association between initial corticosteroid treatment regimen and treatment response time in patients with acetylcholine receptor antibody-positive myasthenia gravis ±èÁøÈñ(¿¬¼¼´ë¼¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 15:50~16:00 Disseminating necrotizing leukoencephalopathy associated with intra-CSF methotrexate chemotherapy for leptomeningeal metastasis ±è±âÈÆ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 16:00~16:10 Relation between arterial compliance and tau burden mediated by amyloid burden and white matter hyperintensities ±è¿©Áø(ÇѸ²´ë°­µ¿¼º½Éº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall B (4F) 16:10~16:20 Head shaking and mastoid oscillation maneuvers in cupulolithiasis of the posterior canal benign paroxysmal positional vertigo : A randomized clinical trial ¿ÀÀºÇý(¾ç»êºÎ»ê´ëº´¿ø)

Åä·Ð 11¿ù 10ÀÏ Convention Hall B (4F) 16:20~16:30 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall C (4F) 14:20~14:45 Education Course : Neuroimaging - Epilepsy ¼±¿ìÁØ»ó(°­ºÏ»ï¼ºº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall C (4F) 14:45~15:10 Education Course : Neuroimaging - Dementia Á¶¼öÇö(Àü³²´ëº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall C (4F) 15:10~15:35 Education Course : Neuroimaging - Movement disorders Á¤½ÂÈ£(ÀÎÁ¦´ë»ó°è¹éº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall C (4F) 15:35~16:00 Education Course : Neuroimaging - Spinal cord disorders ¹ÎÁÖÈ«(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Convention Hall C (4F) 16:00~16:25 Education Course : Neuroimaging - CNS Infection/inflammatory disorders ÀÌ¿ìÁø(ºÐ´ç¼­¿ï´ëº´¿ø)

Åä·Ð 11¿ù 10ÀÏ Convention Hall C (4F) 16:25~16:40 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall A (3F) 14:20~14:40 Cardiovascular dysfunction ¹Ú±âÈ«(¼­¿ïÀÇ·á¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall A (3F) 14:40~15:00 Bladder dysfunction ¹ÚÁø¿ì(°í·Á´ë¾È¾Ïº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall A (3F) 15:00~15:20 Bowel dysfunction ½Åä¿ø(¼¼Á¾Ãæ³²´ëº´¿ø)

Åä·Ð 11¿ù 10ÀÏ Emerald Hall A (3F) 15:20~15:30 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall A (3F) 15:40~16:00 ¿ì¸®³ª¶ó ³ëÀÎÀÇ »çȸÀû °í¸³ ¹× °ü·Ã Á¤Ã¥ÇöȲ Á¶¼º¿ø(º¸°Çº¹ÁöºÎ ³ëÀÎÁ¤Ã¥°ú)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall A (3F) 16:00~16:20 ³ëÀο¡¼­ ¿Ü·Î¿ò°ú ÀÎÁö±â´É Àå¾Ö ±èÅÂÈñ(¿øÁÖ¼¼ºê¶õ½ºº´¿ø Á¤½Å°Ç°­ÀÇÇаú)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall A (3F) 16:20~16:40 ½º¸¶Æ® ÅëÇÕ µ¹º½µµ½Ã »ç¾÷À» ÅëÇÑ ÁßÀç Àå¼÷¶û(Áß¾Ó´ëÇб³ Àû½ÊÀÚ°£È£´ë)

Åä·Ð 11¿ù 10ÀÏ Emerald Hall A (3F) 16:40~16:50 Q&A ()

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall B (3F) 14:20~14:50 K-NEPA 13: What and how? ±èÄ¡°æ(°í·Á´ë±¸·Îº´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall B (3F) 14:50~15:20 ½Å°æ°ú Àü°øÀÇ ¼ö·Ã ½Ã½ºÅÛ °³Æí¹æÇâ ÃÖÈ£Áø(ÇѾç´ë±¸¸®º´¿ø)

±³À°½Ã°£ 11¿ù 10ÀÏ Emerald Hall B (3F) 15:20~15:50 Debriefing and feedback skill À±º¸¿µ(ÀÎÁ¦´ëÀÏ»ê¹éº´¿ø)

Åä·Ð 11¿ù 10ÀÏ Emerald Hall B (3F) 15:50~16:00 Q&A ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦42Â÷ 2023³âµµ ´ëÇѽŰæ°úÇÐȸ Ãß°èÇмú´ëȸ DAY 1 : 2023-11-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦35Â÷ Ãß°èÇмú´ëȸ(1ÀÏÂ÷) : 2023-11-10
´ÙÀ½±Û 2023³â ´ëÇÑÀ§´ëÀå³»½Ã°æÇÐȸ ÀüºÏÁöȸ Ãß°èÇмú´ëȸ : 2023-11-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20805 ¼­¿ï 2024 ´ëÇÑ»ê°ú¸¶ÃëÇÐȸ Á¦27Â÷ Çмú´ëȸ : 2024-06-15 0 5 2024-05-27
20804 ÃæºÏ 204 ÃæûºÏµµÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 9 2024-05-27
20803 ºÎ»ê 2024³â Á¦7ȸ ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ Áý´ãȸ : 2024-06-15 0 4 2024-05-27
20802 ºÎ»ê 2024³â ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ ¿öÅ©¼¥-±â´ÉÀû Æò°¡ ¹× ÁßȯÀÚ ÀçÈ°ÀÇ ½ÇÁ¦ (¿Ü»ó ÁßȯÀÚ Æ÷ÇÔ) : 2024-06-15 0 7 2024-05-27
20801 ¼­¿ï KLASS 20Áֳ⠱â³ä 2024 ´ëÇѺ¹°­°æÀ§Àå°ü¿¬±¸È¸ Á¦27ȸ Á¤±âÇмú´ëȸ : 2024-06-15 0 4 2024-05-27
20800 °æ±â 2024³â Á¦ 3ȸ Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 9 2024-05-27
20799 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø ¾ç¼º±³À° : 2024-06-15 0 6 2024-05-27
20798 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆû¼Ò³â°ú ºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-15 0 2 2024-05-27
20797 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ COPD School 2024 : 2024-06-15 0 2 2024-05-27
20796 ¼­¿ï »óóÀå·ç¿¬±¸È¸ Áý´ãȸ : 2024-06-15 0 3 2024-05-27
20795 Àü³² 2024³â Àü¶ó³²µµÀÇ»çȸ Àü¹Ý±â Çмú´ëȸ : 2024-06-15 0 6 2024-05-27
20794 ¼­¿ï Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Patients with Cardiovascular Disease) 2024 : 2024-06-15 0 2 2024-05-27
20793 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ¾à¹°¾Ë·¹¸£±â ½ÉÆ÷Áö¾ö : 2024-06-15 0 7 2024-05-27
20792 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀü, ÃæûÁöȸ - Á¦3Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-15 0 2 2024-05-27
20791 ¼­¿ï Á¦51ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-06-15 0 6 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷